CD55 抗体 (AA 301-381)
Quick Overview for CD55 抗体 (AA 301-381) (ABIN731228)
抗原
See all CD55 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 301-381
- 
                                            交叉反应
- 人
- 
                                            纯化方法
- Purified by Protein A.
- 
                                            免疫原
- KLH conjugated synthetic peptide derived from human CD55
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- 
                        ELISA 1:500-1000
 FCM 1:20-100
 IHC-P 1:200-400
 IHC-F 1:100-500
 IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            浓度
- 1 μg/μL
- 
                                            缓冲液
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 
                                            储存液
- ProClin
- 
                                            注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            储存条件
- 4 °C,-20 °C
- 
                                            储存方法
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 
                                            有效期
- 12 months
 
- 
                                            
- 
    - CD55 (Complement Decay-Accelerating Factor (CD55))
- 
                                            别名
- CD55/DAF
- 
                                            背景
- 
                        Synonyms: CR, TC, DAF, CROM, Complement decay-accelerating factor, CD55 Background: This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. 
- 
                                            基因ID
- 1604
- 
                                            UniProt
- P08174
- 
                                            途径
- Complement System, Regulation of Leukocyte Mediated Immunity
 抗原
- 
                    
 
                                     
                                     
                                    